FDA Brief

Warning letters Devices

FDA warning letter to

Olympus Medical Systems Corporation

High riskIssued Dec 12, 2022Posted Jan 10, 2023Center for Devices and Radiological Health

Olympus Medical Systems failed to submit timely Medical Device Reports for endoscope malfunctions, FDA says.

What happened

FDA inspected Olympus Medical Systems in Hachioji-shi, Tokyo, Japan, from September 6 to September 9, 2022. FDA found the company did not submit Medical Device Reports (MDRs) within 30 calendar days for complaints showing its Uretero-Reno Fiberscope and Uretero-Reno Videoscope broke or ruptured during use. The company responded on September 30, 2022, saying corrective actions were still ongoing.

What FDA found

  1. Olympus did not submit a Medical Device Report to FDA within 30 calendar days after learning of a device malfunction that could likely cause or contribute to death or serious injury if it recurred.

    21 CFR 803.50(a)(2)
  2. FDA said the endoscopes were misbranded because the firm failed to furnish required information under section 519 of the Act.

    section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2); section 519, 21 U.S.C. § 360i

What FDA wants

FDA asks Olympus to notify it in writing within 15 business days of steps taken to correct the violation and prevent recurrence. FDA also asks for documentation when corrective actions are complete, including a revised MDR procedure and a retrospective review of complaints for reportability.

Who should pay attention

  • hospitals and endoscopy units using Olympus scopes
  • distributors and importers of Olympus medical devices
  • device quality teams responsible for MDR reporting

This is a summary. Read the original letter on fda.gov.

Olympus Medical Systems Corporation's FDA history

  1. Olympus Medical Systems Corporation

    FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.

    High risk
  2. Olympus Medical Systems Corp.

    FDA warned Olympus Medical Systems about endoscope accessories for quality-system, complaint, packaging-seal, and reporting failures.

    High risk

Full company page

Similar letters to other companies

  1. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  2. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  3. O.N. Diagnostics, LLC

    FDA says O.N. Diagnostics sold changed VirtuOst VFA software without required clearance and had quality and reporting failures.

    High risk
  4. Lion Street Medical, d/b/a Pensar Medical LLC

    FDA warns Pensar Medical over unreported wound-therapy injuries and missing device reporting procedures.

    High risk